Satraplatin

Structural formula
General
Non-proprietary name	Satraplatin
other names	( OC-6-43 ) -Bis (acetato- O ) ammine dichloro (cyclohexylamine) platinum; JM216;
Molecular formula	C 10 H 22 Cl 2 N 2 O 4 Pt
External identifiers / databases
PubChem	6918220
DrugBank	DB04996
Wikidata	Q2226212
Drug information
ATC code	L01 XA04
Drug class	Cytostatic
Mechanism of action	Complex formation
properties
Molar mass	500,28 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Satraplatin is the first platinum (IV) complex to be developed for tumor therapy . In contrast to the approved platinum (II) complexes such. B. Cisplatin , satraplatin has a higher lipophilicity , is relatively inert and is absorbed in sufficient quantities from the gastrointestinal tract so that it can be administered orally . Satraplatin is used for hormone-resistant prostate cancer , ovarian cancer and bronchial carcinoma , which cannot be treated with cisplatin. The cytotoxic effect is based on covalent bonds with the DNA of the cancer cells , which lead to the cell cycle remaining in the G ₂ phase and possibly to apoptosis . Before interacting with the DNA, the platinum (IV) complex is converted into the active platinum (II) form by reduction . Satraplatin is thus a prodrug . The plasma half-life is 12 hours.

Satraplatin was developed by the pharmaceutical company Agennix .

literature

Kelland LR, Abel G, McKeage MJ et al .: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug . In: Cancer Research . 53, No. 11, June 1993, pp. 2581-2586. PMID 8388318 . (PDF; 1.23 MB)
Choy H, Park C, Yao M: Current status and future prospects for satraplatin, an oral platinum analogue . In: Clinical Cancer Research . 14, No. 6, March 2008, pp. 1633-1638. PMID 18347164 .
I. Ott, R. Gust: Special features of inorganic cytostatics-medicinal chemistry of the platinum complexes. In: Pharmacy in our time . 2 2006, pp. 124-133.
Sternberg CN, Petrylak DP, Sartor O. et al .: Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial . In: Journal of Clinical Oncology . 27, No. 32, November 2009, pp. 5431-5438. doi : 10.1200 / JCO.2008.20.1228 . PMID 19805692 .
Ricart AD, Sarantopoulos J, Calvo E. et al .: Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study . In: Clinical Cancer Research . 15, No. 11, June 2009, pp. 3866-3871. PMID 19458055 . (PDF; 224 kB)

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.